Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mirvie Granted Breakthrough Device Designation For Test To Identify Risk Of Preeclampsia

Executive Summary

Mirvie’s RNA platform can identify 75% of women who develop preeclampsia months before symptoms occur.

You may also be interested in...



Exec Chat: Israel’s Authority On Medical Robotics Lifts Curtain Behind Technion’s Success Stories

Medtech Insight talked with Moshe Shoham about the innovative technologies behind surgical robotics companies Microbot Medical, XACT Robotics, Tamar Robotics and ForSight Robotics, which were all spun out of his laboratory in Israel.

J&J Medtech Appoints Kurt Van den Bosch As CFO

Kurt Van den Bosch has been named CFO of J&J Medtech where he will report directly to Joe Wolk, J&J’s CFO. 

Microbot Medical Hopes To Bring First Disposable Endovascular Robot To US Market

Microbot Medical CEO Harel Gadot said a recent regulatory filing marks an important milestone in his company' efforts to bring the world’s first fully disposable endovascular robot to market.

Topics

UsernamePublicRestriction

Register

MT145359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel